Table 4 Descriptive comparison of disease activity and medications in use at baseline and after the third qHPV vaccine dose
CMAS (n = 40)a | Cutaneous manifestations (n = 40)a | Medications in use (n = 40)a | |||||
|---|---|---|---|---|---|---|---|
Rash | Gottron’s papules | Heliotrope | |||||
Definition | n (%) | Definition | n (%) | n (%) | n (%) | Definition | n (%) |
Stable with CMAS ≥48 | 24 (60.0) | Stable without cutaneous lesion | 31 (77.5) | 27 (67.5) | 33 (82.5) | Stable without medication | 11 (27.5) |
Stable with CMAS <48 | 11 (27.5) | Stable with cutaneous lesion | 3 (7.5) | 9 (22.5) | 2 (5.0) | Stable with medication | 9 (22.5) |
CMAS Improvement | 5 (12.5) | Improvement of cutaneous lesion | 5 (12.5) | 3 (7.5) | 3 (7.5) | Decreased medication | 14 (35.0) |
CMAS Worsening | 0 (0.0) | Worsening or new-onset of cutaneous lesion | 1 (2.5) | 1 (2.5) | 2 (5.0) | Increased medication | 6 (15.0) |